Over the next few years, as concerns over bioterrorism and infectious diseases rose, the firm won contracts worth more than $1 billion in construction value in the biocontainment market alone, their revenues jumping to more than $4.5 million in 2005 from about $1 million in 1999; of the fifteen or so high-containment labs that existed worldwide in 2006, Smith Carter had been involved, either through consulting or design, in about three-quarters of them, thereby establishing an international reputation in this area.